PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 194,929 shares, an increase of 92.4% from the January 15th total of 101,333 shares. Currently, 73.8% of the company’s shares are short sold. Based on an average daily trading volume, of 6,625,219 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 6,625,219 shares, the short-interest ratio is currently 0.0 days. Currently, 73.8% of the company’s shares are short sold.

PainReform Trading Up 1.7%

PRFX opened at $2.96 on Friday. The stock’s 50-day moving average price is $3.99 and its 200 day moving average price is $5.58. PainReform has a 12-month low of $2.57 and a 12-month high of $27.35. The firm has a market cap of $1.19 million, a price-to-earnings ratio of 0.00 and a beta of 0.61.

PainReform (NASDAQ:PRFX) last issued its quarterly earnings results on Wednesday, October 1st. The company reported ($2.72) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.